Explore more Johnson & Johnson sites:
Jump to:
Responsible Supply Base
Responsible Supply Base
Responsible Supply Base
Responsible Supply Base
We collaborate with suppliers that not only provide the highest quality products and services but who are also philosophically and strategically aligned with our commitment to our social, economic and environmental responsibilities.
The Onward Sustainability Program empowers our partners to hone their sustainability performance and ensure accordance with our joint goals, policies and obligations.
Leveraging our resources and working with our suppliers to drive environmental improvements
Supporting economic inclusion and job creation for underserved populations by partnering with an inclusive and diverse supplier base
Sourcing from suppliers who meet our Responsibility Standards
Health for Humanity and ESG
-
Our extended supply chain comprises about 45,000 suppliers across our three business segments in virtually all countries of the world.
-
Our Health for Humanity 2025 Goals represent an ambitious next step in our journey to profoundly impact the trajectory of health for billions of people.
Additional Policies and Resources
More from Johnson & Johnson
-
Over the past few decades, advances in the study and treatment of this inflammatory bowel disease have rapidly accelerated. We spoke to the experts to learn the latest about managing Crohn's disease—and what other potential breakthroughs are on the horizon.
-
Johnson & Johnson's Brian Woodfall, M.D., was working at a Vancouver clinic in the mid-1990s. That's where he met Tiko Kerr, who became one of the first patients to take the company's HIV medicines—and has thrived to this day. For National AIDS Awareness Month, watch as Kerr, Dr. Woodfall and fellow researcher Joss J. De Wet, M.D., reflect on how those treatments have saved lives and continue to evolve, in this moving video.
-
What do diseases like multiple myeloma and lupus have in common? They're more prevalent in people of color—yet historically these patients have been left out of clinical research, often to dire health consequences. Learn how Johnson & Johnson is working to make the study of conditions like these more equitable.
